DaVita achieves target fistula usage rate in Virginia

DaVita Inc. (NYSE: DVA), a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), has been recognized in the state of Virginia for reaching the End Stage Renal Disease (ESRD) Network's patient quality improvement goal. DaVita(R) strives to maximize the well-being and health of dialysis patients in Virginia by promoting increased use of fistulas, thereby minimizing the risk of complications.

The Fistula First Breakthrough Initiative - or the National Vascular Access Improvement Initiative - is a nationwide campaign to increase the use of arterial venous fistulas (AVFs) in dialysis patients, which are believed to reduce infections and improve clinical outcomes. The Fistula First initiative was launched July 1, 2003, by the Centers for Medicare and Medicaid Services (CMS) along with the 18 ESRD Networks and the Institute of Healthcare Improvement (IHI).

ESRD Network 5 monitors dialysis facilities in Virginia and recently recognized those clinics that have reached or are nearing a target fistula usage rate of 50 percent or greater, directionally consistent with nationwide goals of improving outcomes for ESRD patients.

Newly released data shows that DaVita represents 53 percent of all facilities achieving a target fistula usage rate of 50 percent or greater in the state of Virginia. The next best provider represented 34 percent of the recognized facilities - meaning DaVita has 65 percent more facilities that have achieved the target fistula usage rate. Additionally, the DaVita Front Royal Dialysis clinic was just one of three facilities in the state that went above and beyond by reaching an AVF use rate of 70 percent or greater.

The data is also noteworthy because fistula use is one of CMS' four key Clinical Performance Measures of Quality. With its commitment to following these measures and striving for excellence, DaVita's clinical outcomes are consistently the best or among the best in the industry.

"At DaVita, our highest priority is optimizing the health care of the approximately 116,000 patients cared for by our professional partners and teammates," said Allen R. Nissenson, MD, FACP, and Chief Medical Officer of DaVita. "We're pleased that this commitment has once again been validated by CMS' Fistula First findings."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Semaglutide reduces urine albumin-to-creatinine ratio in overweight chronic kidney disease patients